These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34993746)

  • 1. Atherosclerosis and Atrial Fibrillation: Double Trouble.
    Abolbashari M
    Curr Cardiol Rep; 2022 Feb; 24(2):67-73. PubMed ID: 34993746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
    Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
    Kawakami S; Yasuda S; Ogawa H
    J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    Cardiovasc Interv Ther; 2020 Jan; 35(1):44-51. PubMed ID: 31281936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial.
    Noda T; Nochioka K; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Yasuda S; Afire Investigators OBOT
    EuroIntervention; 2024 Apr; 20(7):e425-e435. PubMed ID: 38562065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study.
    De Luca L; Di Lenarda A; Rubboli A; Bolognese L; Gonzini L; Fortuni F; Navazio A; Poletti F; Ledda A; Urbinati S; Gabrielli D; Gulizia MM;
    Eur J Intern Med; 2021 Jun; 88():28-34. PubMed ID: 33838988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin versus P2Y
    Fukaya H; Ako J; Yasuda S; Kaikita K; Akao M; Matoba T; Nakamra M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Heart; 2021 Nov; 107(21):1731-1738. PubMed ID: 34261738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED;
    Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation.
    Dzeshka MS; Lip GY
    Heart Fail Clin; 2016 Apr; 12(2):257-71. PubMed ID: 26968670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial.
    Cho MS; Kang DY; Oh YS; Lee CH; Choi EK; Lee JH; Kwon CH; Park GM; Park HW; Park KH; Park KM; Hwang J; Yoo KD; Cho YR; Kim YR; Hwang KW; Jin ES; Kim PJ; Kim KH; Park DW; Nam GB
    Am Heart J; 2022 May; 247():123-131. PubMed ID: 35149036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
    Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ
    Contemp Clin Trials; 2015 Jul; 43():129-32. PubMed ID: 26003433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.